SourceOne Tech, Kaneka QH Launch in German Product

CHICAGO Green Power Health Products B.V., The Netherlands, is launching a platform of heart-healthy products featuring the patented VESIsorb® absorption technology, which was developed by SourceOne Global Partners. This latest partnership with Green Power signifies a growing consortium of leveraged networks pioneered by SourceOne to bring branded ingredients and technologies throughout the world.

The first product in the line from Green Power, a direct-to-consumer brand marketer in Germany, contains Kaneka QH Ubiquinol (from Kaneka, Pasadena, TX) in Licaps®, a two-piece, hard-shell capsule delivery system developed by Capsugel, Colmar, France.

We are very selective in the products we put my name behind as well as the name of Green Power," said Reinhard Hittich, president of GreenPower and the formulator behind the popular Dr. Hittich brand. The VESIsorb® system ensures we provide a QH Ubiquinol formulation that optimizes absorption and ensures maxim bioavailability. Accordingly we have branded our product Ultra Ubiquinol Q10 with MAXEffect®."

Jesse Lopez, Founder and CEO of SourceOne, added, "With Dr. Hittich, we continue to focus on aligning our innovative formulations and advanced delivery system technologies with global brand marketing leaders, ensuring a growing number of consumers understand there are significant product differences."

According to Andreas Supersaxo, director of research and development for Vesifact of Baar, Zurich, and member of SourceOnes medical and scientific board, a pharmacokinetic pilot study (single, oral-dose, crossover) in humans that compared Kaneka QH Ubiquinol  to the same Kaneka QH Ubiquinol formulated in the VESIsorb® delivery system (CoQsource® QH Ubiquinol exclusively from SourceOne) demonstrated an increase of 696 percent in peak blood levels (cmax) of Ubiquinol. The relative bioavailability calculated using the area under the curve (AUC0-24h) was also increased by 485 percent.

Supersaxo also noted a second is a peer-reviewed study titled, "Relative Bioavailability Comparison of Different Coenzyme Q10 Formulations with a Novel Delivery System," appearing in the journal, Alternative Therapies in Health and Medicine, (March/April 2009, Vol. 15, No.2) published the results of a double-blind study comparing the bioavailability of patented CoQsource® Bio-Enhanced CoQ10 (CoQ10 formulated in the VESIsorb delivery system) to that of other bio-enhanced" CoQ10 formulations.  In this study, the relative bioavailability of a single oral dose of 120mg of CoQ10 was assessed using the area under curve (AUC (0-10h)) where the value for CoQsource® reached 30.62 µg/ml/10h; a superior 622 percent higher bioavailability than the oil-based formula.